{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:13Z","timestamp":1790649733533,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The tuberculin skin test has significant limitations for use in individuals vaccinated with BCG. The presence in the genome of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> of the RDI region, which is absent in the genome of Mycobacterium bovis BCG and most non-tuberculous mycobacteria, made it possible to develop new skin tests, which include a skin test with a recombinant tuberculosis allergen [RTA (Diaskintest\u00ae, JSC Generium, Russia)]. Diaskintest has shown high diagnostic performance in clinical trials and in conditions of high prevalence of tuberculosis infection. In 2021, the Russia was excluded from the WHO list of high TB burden countries, which makes relevant an assessment of the specificity of the RTA test under conditions of low epidemiologic risk for tuberculosis to confirm the high specificity of the test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study objective<\/jats:title><jats:p>To assess the specificity of Diaskintest in the regions of the Russian Federation with low epidemiologic risk for tuberculosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicenter, open-label, prospective study was conducted, which included 150 healthy volunteers aged 18\u201330\u2009years old, vaccinated with BCG, who were not at risk of tuberculosis, from regions with low epidemiologic risk (Oryol region, Ryazan region, and Arkhangelsk region). During the study, 4 visits were scheduled for each participant: [Visit 0 (screening), Visit 1, Visit 2 (in 72\u2009h) and Visit 3 (in 28\u2009days)]. All participants, who excluded active and latent tuberculosis infection, underwent a test with RTA. To assess the safety of RTA tests, all systemic and local adverse events that occurred during 28\u2009days were recorded. The trial was filed in the NIH clinical trials database <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> (NCT05203068).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In individuals with a negative T-SPOT.TB test, the specificity of the RTA test was 97% (95% CI: 92\u201399%) with a cut-off of &amp;gt;0\u2009mm. The study findings confirm data 2009: 100.00 (95% CI: 94\u2013100). When evaluating the safety of the RTA test during 28\u2009days of follow-up, the participants did not report local and systemic adverse reactions that had a causal relationship with the RTA test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Diaskintest is highly specific and safe, therefore it is a valuable tool as a screening test for early detection of tuberculosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1042461","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T06:56:10Z","timestamp":1677653770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of the specificity of an intradermal test with recombinant tuberculosis allergen in Bacillus Calmette\u2013Gu\u00e9rin-vaccinated healthy volunteers"],"prefix":"10.3389","volume":"10","author":[{"given":"Irina A.","family":"Vasilyeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina A.","family":"Aksenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Kazakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia Y.","family":"Kiseleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey O.","family":"Maryandyshev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N.","family":"Dolzhenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Abramchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadejda I.","family":"Klevno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin A.","family":"Glebov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Panova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa Y.","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena G.","family":"Sheikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna V.","family":"Seregina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena I.","family":"Nikishova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia P.","family":"Doktorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia G.","family":"Samoilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"ref1","volume-title":"Global Tuberculosis Report 2021","year":"2021"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref3","first-page":"1192","article-title":"False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?","volume":"10","author":"Farhat","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1473-3099(18)30355-4","article-title":"Prognostic value of interferon-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study","volume":"18","author":"Abubakar","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1183\/13993003.01910-2015","article-title":"Diagnostics for latent TB infection: incremental, not transformative progress","volume":"47","author":"Pai","year":"2016","journal-title":"Eur Respir J"},{"key":"ref6","article-title":"Fusion protein CFP10-ESAT6, inducing a delayed-type hypersensitivity reaction against M. tuberculosis, a chimeric nucleic acid encoding it and a recombinant plasmid expression vector containing it, a method for producing a fusion protein and a dosage form for intradermal injection based on it","volume":"2360926","author":"Kiselev","year":"2008","journal-title":"Patent RF"},{"key":"ref7","year":""},{"key":"ref8","year":""},{"key":"ref9","year":""},{"key":"ref10","year":""},{"key":"ref11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1473-3099(21)00261-9","article-title":"The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-\u03b3 release assays: a systematic review and meta-analysis","volume":"22","author":"Krutikov","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ref12","volume-title":"Instruction for medical use of pharmaceutical product Diaskintest\u00ae","year":""},{"key":"ref13","year":""},{"key":"ref14","year":""},{"key":"ref15","first-page":"1","article-title":"New skin test for the diagnosis of tuberculosis","volume":"1","author":"Litvinov","year":"2009","journal-title":"Russ. Med. J"},{"key":"ref16","first-page":"1","article-title":"Clinical studies of a new skin test Diaskintest\u00ae for the diagnosis of tuberculosis","volume":"2","author":"Kiselev","year":"2009","journal-title":"Tuberculosis and Lung Diseases"},{"key":"ref17","first-page":"37","article-title":"Sensitivity of a test with recombinant tuberculosis allergen containing CFP10-ESAT6 protein in newly diagnosed children and adolescents with tuberculosis in Moscow","volume":"2","author":"Slogotskaya","year":"2013","journal-title":"Tuberc Soc Signif Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.15690\/pf.v12i1.1255","article-title":"Efficiency of a skin test with recombinant tuberculosis allergen in detecting tuberculosis in children and adolescents in Moscow in 2013","volume":"12","author":"Slogotskaya","year":"2015","journal-title":"Pediatr Pharmacol"},{"key":"ref19","first-page":"116","article-title":"Sensitivity and specificity of Diaskintest in extrapulmonary TB in patients with and without HIV infection","volume":"3","author":"Slogotskaya","year":"2011","journal-title":"Immunology"},{"key":"ref20","first-page":"10","article-title":"Latent tuberculosis infection in risk groups in the adult population of Moscow, 2012\u20132016","volume":"2","author":"Bogorodskaya","year":"2017","journal-title":"Tuberc Soc Signif Dis"},{"key":"ref21","first-page":"56","article-title":"Diagnostic capabilities of recombinant tuberculosis allergen in screening for tuberculosis infection in adolescent children in the Ryazan region","volume":"6","author":"Dolzhenko","year":"2015","journal-title":"Tuberc Lung Dis"},{"key":"ref22","first-page":"49","article-title":"Comparison of the results of the Mantoux test with 2 TU and Diaskintest in various manifestations of tuberculosis infection","volume":"6","author":"Korneva","year":"2013","journal-title":"Tuberc Lung Dis"},{"key":"ref23","first-page":"153","article-title":"Epidemiological factors and immunological tests in the establishment of risk groups for tuberculosis","volume":"5","author":"Poddubnaya","year":"2015","journal-title":"Tuberc Lung Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20953\/1817-7646-2016-4-9-17","article-title":"Effectiveness of different screening methods for early diagnosing tuberculosis in children and adolescents","volume":"11","author":"Aksenova","year":"2016","journal-title":"Clin Pract Pediat"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.5588\/ijtld.11.0829","article-title":"Comparison of specificities between two interferon-gamma release assays in Japan","volume":"16","author":"Higuchi","year":"2012","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1042461\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T06:56:29Z","timestamp":1677653789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1042461\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":25,"alternative-id":["10.3389\/fmed.2023.1042461"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1042461","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"article-number":"1042461"}}